Beta Bionics BBNX 深 沪
等待开盘 09-01 09:30:00 美东时间
19.95
+0.230
+1.17%
华盛通- 最 高20.00
- 今 开19.42
- 成交量 43.49万股
- 最 低 19.02
- 昨 收 19.72
- 总市值 8.98亿
- 52周最高 32.71
- 市盈率 静 --
- 换手率 0.97%
- 52周最低 8.80
- 委 比 98.02%
- 总股本 4498.97万
- 历史最高 32.71
- 量 比 0.60
- 振 幅 4.97%
- 历史最低 8.80
- 每 手 1
- 风险率 6.75%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多William Blair Initiates Coverage On Beta Bionics with Market Perform Rating
William Blair analyst Steven Lichtman initiates coverage on Beta Bionics (NASDAQ:BBNX) with a Market Perform rating.
08-22 04:15
Innovative Insulin Pumps Drive Optimism for Tandem, Beta Bionics
On Friday, William Blair initiated coverage on Tandem Diabetes Care Inc. (NASDAQ:TNDM) and Beta Bionics Inc (NASDAQ:BBNX), noting that both companies are advancing initiatives to play in faster-growing segments of the insulin pump market. Both companies have the potential to benefit from market expa...
08-22 01:31
Beta Bionics Affirms FY2026 Sales Guidance of $131.000M-$136.000M vs $133.305M Est
Beta Bionics (NASDAQ:BBNX) affirms FY2026 sales outlook from $131.000 million-$136.000 million to $131.000 million-$136.000 million vs $133.305 million estimate.
07-30 04:03
Beta Bionics Q2 EPS $(0.53) Beats $(0.56) Estimate, Sales $32.013M Beat $31.443M Estimate
Beta Bionics (NASDAQ:BBNX) reported quarterly losses of $(0.53) per share which beat the analyst consensus estimate of $(0.56) by 5.36 percent. This is a 35.9 percent decrease over losses of $(0.39) per share from the same period last year. The company reported quarterly sales of $32.013 million whi...
07-30 04:03
美股大行评级 | 潜在涨幅284.62%！Annexon获Needham上调目标价至25美元；多家大行上调美国银行目标价
今日重点评级关注：Needham：维持Annexon"买入"评级，目标价从11美元升至25美元；Benchmark：维持Prenetics Global"买入"评级，目标价从30美元升至40美元
07-16 18:55
美股大行评级 | 花旗上调苹果、西部数据、希捷科技、超微电脑等目标价；高盛上调蔚来"买入"评级，目标价7美元
今日重点评级关注：HC Wainwright & Co.：维持艾吉纳斯"买入"评级，目标价从23美元升至30美元；富国银行：上调Q32 Bio评级至"超配"，目标价66美元
07-14 11:36
Truist Securities Maintains Buy on Beta Bionics, Raises Price Target to $22
Truist Securities analyst Richard Newitter maintains Beta Bionics (NASDAQ:BBNX) with a Buy and raises the price target from $18 to $22.
07-14 00:09
Beta Bionics Announces Near Real-Time Real-World Data On iLet Bionic Pancreas Is Now Publicly Available At betabionics.com/hcp/real-world-data
Beta Bionics, Inc. (NASDAQ:BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced that near real-time real-world data on the iLet Bionic Pancreas is now publicly
06-02 21:09
美股大行评级 | 潜在涨幅99.91%！Tigress Financial上调英伟达目标价至425美元，维持"强力买入"评级
今日重点评级关注：Tigress Financial：维持英伟达"强力买入"评级，目标价从360美元升至425美元；康托·菲茨杰拉德：维持DeFi Development"超配"评级，目标价从6美元升至7美元
05-28 19:00
Goldman Sachs Maintains Buy on Beta Bionics, Lowers Price Target to $17
Goldman Sachs analyst David Roman maintains Beta Bionics (NASDAQ:BBNX) with a Buy and lowers the price target from $19 to $17.
05-28 01:32
